Acute Coronary Syndrome
Atherothrombosis
Cardiac Imaging
Dyslipidemia
- Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
- PREVAIL: Obicetrapib in ASCVD
- Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk
- Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial
- Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial
- An “Inclisiran First” Strategy vs Usual Care in Patients With Atherosclerotic Cardiovascular Disease
- ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
- ACC Statin Intolerance Tool
- Cholesterol Tools and Resources
Familial Chylomicronemia Syndrome (FCS)
- Recognition and management of persistent chylomicronemia
- NAFCS Score for FCS: Development and validation
- NAFCS Score Calculator for FCS
- Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome
- Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
- Patient Tear Sheet: What You Need to Know-FCS
- Qualitative development of the PROMIS Profile v1.0-Familial Chylomicronemia Syndrome (FCS) 28
- Understanding FCS – for Patients
- About FCS
Familial Hypercholesterolemia (FH)
Heart Failure (HF)
- Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials: JACC Review Topic of the Week
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial
- Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF
- Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes
- Clinical Outcomes and Response to Vericiguat According to Index Heart Failure Event: Insights From the VICTORIA Trial
- Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
- Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure
- Heart Failure: Patient Education
Hypertension
Hypertriglyceridemia
- Target Populations for Novel Triglyceride-Lowering Therapies
- Triglycerides. MedlinePlus.
- Fish and Omega-3 Fatty Acids
Hypertrophic Cardiomyopathy (HCM)
- Provider Tools: AHA HCM Educational Resources
- Provider Tools: Genetic Testing and Counseling for HCM
- Talking With Patients About Hypertrophic Cardiomyopathy
- Mavacamten Prescribing Information
- Mavacamten REMS (Risk Evaluation and Mitigation Strategy)
- Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- VALOR-HCM: A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy
- Risk Stratification in HCM
- Hypertrophic Cardiomyopathy Association (HCMA)
- Encouraging Shared Decision Making in HCM
- Patient Info: HCM Action Plan
- Patient Info: HCM Fact Sheets
- Patient Info: HCM Genetic Testing
- Patient Info: Hypertrophic Cardiomyopathy
Lipoprotein (a) [Lp(a)]
- Patient Resource: What is Lipoprotein(a)?
- Patient Resource: Treating High Lp(a)
- Assessing Risk: Infographic on Lp(a) Screening
